8-K: Aardvark Doses First Patient in Phase 3 PWS Trial

Aardvark Therapeutics announced the dosing of the first patient in Australia for its Phase 3 HERO trial of ARD-101 for Prader-Willi syndrome, maintaining its Q3 2026 data readout timeline.

Summary

• The first patient has been dosed in Australia in the Phase 3 HERO pivotal clinical trial assessing ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi syndrome (PWS).
• Regulatory clearance for enrollment by clinical trial sites in Canada and the United Kingdom participating in the HERO trial has been received, with enrollment expected to initiate shortly.
• Based on strong enrollment in the US and continued international progress, the company anticipates not needing to activate previously planned sites in the EU to fully enroll the HERO trial.
• The clinical trial continues to track towards a topline data readout in the third quarter of 2026.
• All patients who have completed the 12-week clinical trial to date have successfully enrolled and remain in the Open Label Extension trial, indicating strong patient interest and engagement.
• The HERO trial (NCT06828861) plans to enroll 90 patients across the US, Australia, Canada, the United Kingdom, and South Korea.
• ARD-101 has been granted both Orphan Drug Designation and Rare Pediatric Disease Designation by the FDA for PWS.

Sentiment

Score: 7

Explanation: The announcement is positive, confirming the Phase 3 trial is progressing as planned with strong patient interest and maintaining its timeline. The ability to potentially forgo EU sites due to strong enrollment elsewhere is a positive operational sign. However, it's a clinical trial update, not a data readout, so the sentiment is cautiously optimistic, reflecting progress without definitive efficacy results.

Positives

• First patient dosed in Australia for the Phase 3 HERO trial, expanding the global reach of the study.
• Regulatory clearance received for clinical trial sites in Canada and the United Kingdom, enabling further international enrollment.
• Strong enrollment in the US and international progress indicate the company may not need to activate previously planned EU sites, potentially streamlining the trial process.
• The trial remains on track for its anticipated topline data readout in Q3 2026, adhering to the projected timeline.
• All patients who have completed the 12-week clinical trial have enrolled in the Open Label Extension trial, suggesting high patient interest and engagement.
• ARD-101 holds FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Prader-Willi Syndrome, highlighting its potential for addressing an unmet medical need.

Risks

• Uncertainties related to potential delays in the commencement, enrollment, and completion of clinical trials.
• The risk that capital resources may be used sooner than expected and could be insufficient to allow the company to achieve its anticipated milestones.
• Dependence on third parties for manufacturing, shipping, and production of drug product for use in clinical trials and preclinical studies.
• The risk of unfavorable clinical trial results.
• The risk that results from earlier clinical trials and preclinical studies may not necessarily be predictive of future results.
• Other risks and uncertainties, including factors described under the Risk Factors section of Aardvark's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.

Future Outlook

Aardvark Therapeutics anticipates that the Phase 3 HERO trial for ARD-101 in Prader-Willi syndrome will achieve its topline data readout in the third quarter of 2026, supported by strong enrollment in the US and international sites, potentially negating the need for previously planned EU sites. The company is also developing ARD-201, a planned fixed-dose combination of ARD-101 with a DPP-4 inhibitor, through two separate Phase 2 trials with a goal of addressing some of the limitations of currently marketed GLP-1 therapies for obesity and obesity-related conditions.

Management Comments

• "We have seen very strong interest in the HERO trial within the patient community, which has been driving enrollment in the United States and in our newly opened Australia sites." Tien Lee, M.D., Founder and Chief Executive Officer of Aardvark.
• "All patients who have completed the 12-week clinical trial to date have enrolled in the Open Label Extension trial, which is an encouraging indicator of patient interest and engagement." Tien Lee, M.D., Founder and Chief Executive Officer of Aardvark.
• "It's important to note that significant unmet needs continue to persist in the PWS community, and many families are eager for a therapy that could ameliorate the relentless hunger that is a hallmark of PWS." Manasi Jaiman, M.D., Chief Medical Officer of Aardvark.

Industry Context

This announcement highlights continued progress in the development of novel therapeutics for rare metabolic diseases, specifically Prader-Willi syndrome, which has significant unmet medical needs. The focus on gut-restricted small molecules and activation of innate homeostatic pathways represents an innovative approach in a field increasingly dominated by GLP-1 agonists, with Aardvark also exploring complementary uses with existing anti-appetite therapies. The strong patient interest and enrollment rates suggest a high demand for effective treatments in this niche.

Comparison to Industry Standards

• The HERO trial's design as a randomized, double-blind, placebo-controlled Phase 3 trial with 90 patients is standard for pivotal studies aiming for regulatory approval in rare diseases.
• The use of HQ-CT, CaGI-S, and CGI-S as primary and secondary endpoints aligns with common clinical assessment tools for hyperphagia and overall disease severity in PWS, similar to trials conducted by competitors like Rhythm Pharmaceuticals (setmelanotide for PWS) or Soleno Therapeutics (d-fenfluramine for PWS).
• The ability to maintain the Q3 2026 topline data readout timeline, despite global enrollment complexities, suggests efficient trial management, which is a positive indicator compared to many clinical trials that face delays.
• The high enrollment rate into the Open Label Extension trial is a strong indicator of patient and caregiver satisfaction or perceived benefit, which can be a positive signal for drug efficacy, though not a direct measure of it.

Stakeholder Impact

• Shareholders: Positive news regarding clinical trial progress and adherence to timelines could instill confidence, potentially supporting stock value.
• Patients (Prader-Willi Syndrome): Continued progress in the HERO trial offers hope for a new therapeutic option to address hyperphagia, a significant unmet need.
• Employees: Positive momentum in the lead clinical program can boost morale and reinforce the company's mission.
• Regulatory Authorities: The receipt of Orphan Drug and Rare Pediatric Disease Designations, along with ongoing Phase 3 development, demonstrates adherence to regulatory pathways for novel therapies.

Next Steps

• Initiate enrollment in Canada and the United Kingdom shortly.
• Continue enrollment for the Phase 3 HERO trial across US, Australia, Canada, UK, and South Korea.
• Anticipate topline data readout from the HERO trial in Q3 2026.
• Continue development of ARD-201 in two separate Phase 2 trials for obesity and obesity-related conditions.

Key Dates

Recommendation

The company is making expected progress in its pivotal Phase 3 trial for ARD-101, with strong enrollment and adherence to the timeline for topline data in Q3 2026. This is a positive operational update for a clinical-stage biopharmaceutical company. However, no efficacy data has been released, and significant risks inherent in clinical development, such as potential for unfavorable trial results, remain. Therefore, a "hold" recommendation is appropriate for a seasoned investor, awaiting the critical topline data readout before making a more definitive investment decision.

Keywords

Aardvark Therapeutics, ARD-101, Prader-Willi Syndrome, PWS, Hyperphagia, Phase 3 Clinical Trial, HERO Trial, Biopharmaceutical, Orphan Drug, Rare Pediatric Disease, Clinical Development, Metabolic Diseases, GLP-1, CCK